Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18569063 | 0.87 | MAPT (0.57) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL260421 | 0.83 | LMNA (0.54) | MAPTLMNAKDM4EALDH1A1POLB | |
| SCHEMBL29828863 | 0.82 | CYP3A4 (0.58) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL279841 | 0.82 | MAPT (0.50) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL11386835 | 0.81 | KDM4E (0.72) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL11387211 | 0.80 | CYP1A2 (0.66) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL1679708 | 0.79 | CYP3A4 (0.54) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL11395592 | 0.78 | CYP1A2 (0.56) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL260409 | 0.77 | MAPT (0.51) | MAPTCYP3A4CYP1A2CYP2C19LMNA | |
| SCHEMBL266592 | 0.77 | CYP3A4 (0.61) | MAPTCYP3A4CYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-7579477-B2 | Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2009-08-25 | — | — | US | disclosed |
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | disclosed |
| US-20080233163-A1 | Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-09-25 | — | — | US | disclosed |
| US-7368577-B2 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-05-06 | — | — | US | disclosed |
| US-7332513-B2 | Thiazole-based nitric oxide donors having acyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-02-19 | — | — | US | disclosed |
| US-7189750-B2 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2007-03-13 | — | — | US | disclosed |
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105065-A2 | THIAZOLE-BASED NITRIC OXIDE DONORS FOR TREATING INFLAMMATORY BOWEL DISEASES | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233163-A1 | Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | MAPT 4020/4885CYP3A4 152/4885CYP1A2 164/4885 |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | MAPT 3098/4885CYP3A4 80/4885CYP1A2 138/4885 |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | NOS2, NOS1, NOS3 | MAPT 4152/4885CYP3A4 40/4885CYP1A2 46/4885 |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | MAPT 4020/4885CYP3A4 152/4885CYP1A2 164/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | MAPT 3663/4885CYP3A4 121/4885CYP1A2 143/4885 |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | NOS2, NOS1, NOS3 | MAPT 4219/4885CYP3A4 162/4885CYP1A2 168/4885 |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | NOS1, NOS2, NOS3 | MAPT 4115/4885CYP3A4 50/4885CYP1A2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.